FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

vvasiiiigi	Join, D.C.	20040

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	OMB APPROVAL								
	OMD Number	2225 0207							
		DMB Number: 3235-0287 Estimated average burden							
Estimated average burden		urden							
	hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Lock Kenneth A.					2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ ARQT ]  5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director To Officer (give title Other (specify below)									ner				
(Last)	(Last) (First) (Middle) C/O ARCUTIS BIOTHERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 10/15/2020							Chief Commercial Officer					
		E ROAD, SUITE	1															
(Street) WESTLAKE VILLAGE CA 91361				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)															
		Tab	le I - Non-I	Derivativ	e Se	curit	ies Ac	quired,	Dis	posed o	of, or Be	neficia	lly Owne	t.				
Date			. Transaction Date Month/Day/Y	Execution Date,		e, Transaction Disposed Of Code (Instr. 5)		ties Acquired (A) or I Of (D) (Instr. 3, 4 an		Benefic	es For ally (D) Following (I) (		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									v	Amount	(A) o (D)	r Price	Transac (Instr. 3	tion(s)			(111501.4)	
Common	Stock			10/15/202	/2020		M <sup>(1)</sup>		7,500	7,500 A \$		2 16,	16,500(2)		D			
		T	able II - De (e.	erivative .g., puts,									y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Code	Transaction Code (Instr.		umber ivative urities juired or coosed D) tr. 3, 4	6. Date Exercisable an Expiration Date (Month/Day/Year)			d 7. Title and Amount of Securities Underlying Derivative Sect (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$6.52	10/15/2020		M <sup>(1)</sup>			7,500	(3)	10	0/28/2029	Common Stock	7,500	\$0	152,443	3	D		

## **Explanation of Responses:**

- 1. Reflects cash exercise of stock option without the disposition of the underlying shares.
- 2. Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
- 3. The option began vesting as to 1/4 of the total shares on October 14, 2020, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on October 14, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

/s/ John W. Smither, as

Attorney-in-Fact for Kenneth

A. Lock

\*\* Signature of Reporting Person Date

10/16/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.